Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct-Dec;10(4):363-369.
doi: 10.4103/JLP.JLP_36_18.

Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?

Serife Solmaz  1 , Ozcan Uzun  2 , Celal Acar  1 , Omur Gokmen Sevindik  3 , Ozden Piskin  4 , Hayri Guner Ozsan  4 , Fatih Demirkan  4 , Bulent Undar  4 , Ahmet Alacacioglu  5 , Mehmet Ali Ozcan  4 , Inci Alacacioglu  4
Affiliations

Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?

Serife Solmaz et al. J Lab Physicians. 2018 Oct-Dec.

Abstract

Background: Recent reports showed neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies.

Materials and methods: We retrospectively examined the PLR, NLR, and MLR in a cohort of 186 newly diagnosed multiple myeloma (MM) patients. This study investigated the prognostic relevance of NLR, PLR, and MLR in MM patients. NLR, PLR, and MLR were calculated from whole blood counts before therapy. The Kaplan-Meier curves and multivariate Cox models were used for the evaluation of survival.

Results: Applying cutoff of 1.9 (NLR), 120.00 (PLR), and 0.27 (MLR), decreased PLR showed a negative impact on the outcome. Decreased PLR is an independent predictor for PFS and OS. There were no significant differences in median survival between the high and low NLR (P = 0.80) and MLR (P = 0.87) groups.

Conclusions: In this study, thrombocytopenia and low PLR are associated with poor survival in MM patients does this P value apply to thrombocytopenia or low PLR and may serve as the cost-effective prognostic biomarker.

Keywords: Multiple myeloma; neutrophil-to-lymphocyte ratio; new prognostic marker; platelet-to-lymphocyte ratio.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
(a) The impact of platelet-to-lymphocyte ratio on overall survival in multiple myeloma patients, (b) the impact of platelet-to-lymphocyte ratio on progression-free survival in multiple myeloma patients
Figure 2
Figure 2
(a) The impact of neutrophil-to-lymphocyte ratio on overall survival in multiple myeloma patients, (b) the impact of neutrophil-to-lymphocyte ratio on progression-free survival in multiple myeloma patients
Figure 3
Figure 3
The impact of platelet-to-lymphocyte ratio on progression-free survival according to the international staging system Stages I, II, and III
Figure 4
Figure 4
The impact of platelet-to-lymphocyte ratio on overall survival according to the international staging system Stages I, II, and III
See this image and copyright information in PMC

References

    1. Spicka I. Advances in multiple myeloma therapy during two past decades. Comput Struct Biotechnol J. 2014;10:38–40. - PMC - PubMed
    1. Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385:2197–208. - PubMed
    1. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: Proposed incorporation into the international staging system. Leukemia. 2008;22:1933–7. - PMC - PubMed
    1. Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: A review about the future. J Hematol Oncol. 2016;9:52. - PMC - PubMed
    1. Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis. J Clin Oncol. 2003;21:4239–47. - PubMed